Table 4.
Estimated pharmacokinetic parameters for the patients categorized by rabeprazole treatment day
| Day 1 | Day 4 | Day 7 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HomEM | HetEM | All EM | PM | HomEM | HetEM | All EM | PM | HomEM | HetEM | All EM | PM | |
| CL (l h−1) | 16.8* | 14.8* | 15.8* | 9.75 | 18.6* | 17.7* | 18.0* | 12.6 | 17.8 | 15.7 | 16.7* | 9.87 |
| SD | 2.61 | 3.39 | 3.15 | 2.96 | 4.04 | 3.99 | 3.94 | 3.20 | 8.52 | 5.39 | 6.99 | 2.05 |
| K (1 h−1) | 0.72 | 0.63 | 0.68 | 0.50 | 0.69* | 0.72* | 0.71* | 0.53 | 0.75 | 0.67 | 0.71* | 0.49 |
| SD | 0.16 | 0.18 | 0.17 | 0.25 | 0.07 | 0.07 | 0.07 | 0.08 | 0.32 | 0.14 | 0.25 | 0.08 |
| V (l) | 24.7 | 25.1 | 22.7 | |||||||||
| SD | 10.1 | 4.71 | 3.82 | |||||||||
| Ka (1/h) | 2.26 | 1.91 | 3.55 | |||||||||
| SD | 1.76 | 0.88 | 6.40 | |||||||||
| Alag (h) | 1.33 | 1.71 | 1.44 | |||||||||
| SD | 0.27 | 0.86 | 0.30 | |||||||||
*
Significant difference (P < 0.05) from PM. HomEM, homozygous extensive metabolizers; HetEM, heterozygous extensive metabolizers; EM, extensive metabolizers; PM, poor metabolizers.